Fig 1.
The flow diagram of selecting fondaparinux-related AEs from FAES database.
Fig 2.
Distribution of adverse reactions of fondaparinux in each year.
Table 1.
Epidemiological characteristics of fondaparinux adverse event reports.
Table 2.
The signal strength of AEs of fondaparinux at the SOC level in FAERS database.
Fig 3.
The most relevant preferred terms within the most significant System Organ Classification in fondaparinux.
Table 3.
Stratified analysis of concomitant anticoagulant and antiplatelet exposure in fondaparinux-related major adverse events.
Table 4.
Disproportionality analysis of major fondaparinux-associated adverse events after excluding concomitant anticoagulant and antiplatelet therapies.
Fig 4.
The primary adverse effects of fondaparinux treatment in men and women.
Fig 5.
Time to Onset of Adverse Reactions Associated with Fondaparinux.